Search

The present work is concerned with tailoring and appraisal of a novel nano-cargo; bilosomes (BLS) dual laded with doxylamine succinate (DAS) and pyridoxine hydrochloride (PDH), the first treatment option against gestational nausea and vomiting, for intranasal delivery. This bifunctional horizon could surmount constraints of orally-commercialized platforms both in dosage regimen and pharmacokinetic profile. For accomplishing this purpose, DAS/PDH-BLS were elaborated integrating phospholipid, sodium cholate and cholesterol applying thin-film hydration method based on Box-Behnken design. Utilizing Design-Expert® software, the effect of formulation variables on BLS physicochemical features alongside the optimal formulation selection were investigated. Then, the optimum DAS/PDH-BLS formulation was incorporated into a thermally-triggered in situ gelling base. The in vivo pharmacokinetic studies were explored in rats for intranasal DAS/PDH-BLS in situ gel compared with analogous intranasal free in situ gel and oral solution. The optimized BLS disclosed vesicle size of 243.23 nm, ζ potential of -31.33 mV, entrapment efficiency of 59.18 and 41.63%, accumulative % release within 8 h of 63.30 and 85.52% and accumulative permeated amount over 24 h of 347.92 and 195.4 µg/cm2 for DAS/PDH, respectively. Following intranasal administration of the inspected BLS in situ gel, pharmacokinetic studies revealed a 1.64- and 2.3-fold increment in the relative bioavailability of DAS and a 1.7- and 3.73-fold increase for PDH compared to the intranasal free in situ gel and oral solution, respectively besides significantly extended mean residence times for both drugs. Thus, the intranasally exploited DAS/PDH-BLS could be deemed as a promising hybrid nanoplatform with fruitful pharmacokinetics and tolerability traits.

Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor systemic availability (14%) after oral administration in addition to other side effects on the gastrointestinal tract, liver and muscle.The goal of the present investigation was to improve ATV bioavailability and overcome complications attendant with peroral administration by developing a new nanovesicular system encapsulating ATV for its delivery via the transdermal route.The vesicular systems were prepared by incorporating different polyethylene glycol fatty acid esters such as Labrasol, Cremophor EL, Gelucire 44/14 and Tween 80 as edge activators (EAs) in the lipid bilayer. The effect of the phosphatidylcholine (PC):EA molar ratio on the physicochemical properties of the vesicles was investigated. The pharmacokinetic studies of the optimized formulation were evaluated in rats. The optimized formulation was tested in poloxamer 407-induced hyperlipidemic rats. The plasma lipid profile, activity of liver enzymes, and oxidative stress parameters were measured using commercially available kits.The results revealed high ATV entrapment efficiency (EE%) ranging from 55.62 to 83.91%. The formulations that contained Labrasol showed the highest EE%. The mean diameter of the vesicles was in the range of 186-583nm. T8 containing Gelucire 44/14 as an EA in the molar ratio of 15:1 (PC:EA) gave the smallest size and exhibited the best permeation parameters across the skin. The pharmacokinetic studies revealed that about three times statistically significant (p0.05) improvement in bioavailability, after transdermal administration of nanotransfersomal ATV gel compared to oral ATV suspension. The transdermal vesicular system exhibited a significant decrease in plasma total cholesterol, triglycerides and LDL cholesterol comparable to oral ATV. Additionally, it lowered the malondialdehyde levels in plasma and abolished the increase in liver enzyme activity.The results obtained suggest that the proposed transdermal vesicular system can serve as a promising alternative means for delivery of ATV.

The objective of this study was formulation, development and evaluation of meloxicam orodispersible tablets. ODTs were prepared by two methods including sublimation technique where different subliming agents like camphor, menthol and thymol were used with Ac-Di-Sol as a superdisintegrant. Each subliming agent was used in three different concentrations (5, 10 and 15% w/w). Tablets were first prepared and later exposed to vacuum. Meloxicam ODTs were also prepared by freeze-drying an aqueous dispersion of meloxicam containing a matrix former, a sugar alcohol, and a collapse protectant. In addition, different disintegration accelerators were tested (each in 1% w/v) including PVP K25, PVP K90, PEG 6000, PEG 4000, PEG 400, tween 80 and tween 20. The prepared ODTs from two methods were evaluated for weight variation, thickness, drug content, friability, hardness, wetting time, in vitro disintegration time and in vitro dissolution study. The best formulation was subjected to stability testing for 3 months at temperatures 40 °C and 75% relative humidity and at 60 °C. All formulations showed disintegration time ranging from 1 to 46 s. All the prepared formulae complied with the pharmacopoeial requirements of the drug contents. T17 gave the best in vitro disintegration and dissolution results. ODT formula T17 has shown no appreciable changes with respect to physical characters, meloxicam content and dissolution profiles when stored at elevated temperatures. In conclusion the results of this work suggest that orodispersible tablets of meloxicam with rapid disintegration time, fast drug release and good hardness can be efficiently and successfully formulated by employing freeze drying and sublimation methods.

Tenoxicam is a poorly water-soluble NSAID drug and dissolution plays an important role in its absorption, so the present investigation was to develop and characterize orodispersible tablets of tenoxicam using solid deposition technique on superdisintegrants in order to improve its dissolution and aqueous solubility to facilitate faster onset of action. The super-disintegrants used were crospovidone, cross-carmellose sodium, sodium starch glycolate and pregelatinised maize starch in ratios of 1:1, 1:2 and 1:4 (w/w) drug:carrier. Drug excipients compatibility study was carried out using DSC, IR spectroscopy and SEM photography. General characterization of the prepared tablets was performed, in addition to wetting time, in vitro disintegration time and in vitro dissolution studies. The formula containing cross-carmellose sodium as a carrier in a ratio of 1:2 showed highest dissolution rate and shortest disintegration time. It was subjected to stability stress testing and drug concentration was detected by stability indicating HPLC assay method and in conclusion, the results of this work suggest that stable rapid release tenoxicam orodispersible tablets can be developed by solid deposition method.